Elan Corporation plc ("Elan") announced that the U.S. Food and Drug Administration approved Myobloc (Botulinum Toxin Type B) Injectable Solution.

New MYOBLOC Ready-to-Use Solution is a liquid formulation of botulinum toxin that does not require reconstitution and is available in three convenient vial configurations of 2,500 Units, 5,000 Units and 10,000 units, providing maximum flexibility for dosing.

Donal J. Geaney, chairman and chief executive officer of Elan, commented, "Our scientists have extensive experience in the development of biological therapeutics, and we've applied this expertise to the development of Myobloc, resulting in the only botulinum toxin therapy available as a ready-to-use solution. We are excited to bring this new product to physicians and their patients."

Elan Corporation plc is a leading worldwide specialty pharmaceutical and drug delivery company headquartered in Ireland, with its principal research, development, manufacturing and marketing facilities located in Ireland, the United States and Israel.